



HAL
open science

Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France

Yann de Rycke, Florence Tubach, Alexandre Lafourcade, Sylvie Guillo, Marie Dalichampt, André Dahlab, Xavier Bresse, Mathieu Uhart, Christine Bergeron, H el ene Borne, et al.

► **To cite this version:**

Yann de Rycke, Florence Tubach, Alexandre Lafourcade, Sylvie Guillo, Marie Dalichampt, et al.. Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France. PLoS ONE, 2020, 15 (2), pp.e0228660. 10.1371/journal.pone.0228660 . inserm-02529912

HAL Id: inserm-02529912

<https://inserm.hal.science/inserm-02529912>

Submitted on 2 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin ee au d ep ot et  a la diffusion de documents scientifiques de niveau recherche, publi es ou non,  emanant des  tablissements d'enseignement et de recherche fran ais ou  trangers, des laboratoires publics ou priv es.


RESEARCH ARTICLE

Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France

Yann de Rycke¹, Florence Tubach¹, Alexandre Lafourcade¹, Sylvie Guillo¹, Marie Dalichamp², André Dahlab³, Xavier Bresse⁴, Mathieu Uhart³, Christine Bergeron⁵, H el ene Borne⁶, Charlotte Cancalon⁷, Audrey Lajoinie⁷, St eve B enard^{7*}

1 Sorbonne Universit , INSERM, Institut Pierre Louis d'Epid miologie et de Sant  Publique, AP-HP, Sorbonne Universit , H pital Piti  Salp tri re, D partement de Sant  Publique, Centre de Pharmaco pid miologie (Cephepi), Unit  de Recherche Clinique PSL-CFX, Paris, France, **2** Biostatistics consultant, Nantes, France, **3** Sanofi Pasteur MSD, Lyon, France, **4** MSD Vaccins, Lyon, France, **5** Laboratoire Cerba, Cergy-Pontoise, France, **6** Gynecologist, Paris, France, **7** st eve consultants, Oullins, France

* sbenard@steve-consultants.com



OPEN ACCESS

Citation: de Rycke Y, Tubach F, Lafourcade A, Guillo S, Dalichamp M, Dahlab A, et al. (2020) Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France. PLoS ONE 15(2): e0228660. <https://doi.org/10.1371/journal.pone.0228660>

Editor: Linus Chuang, University of Vermont Larner College of Medicine, UNITED STATES

Received: July 8, 2019

Accepted: January 21, 2020

Published: February 13, 2020

Copyright:   2020 de Rycke et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Study methods were validated by a multidisciplinary qualified independent scientific committee (ISC). This observational study used existing claims data (SNDS, including EGB and PMSI databases). According to the French legislation at the time of study implementation, process to access such administrative database did not involve submission to an ethics committee. Since the study used existing data from the SNDS, patients did not need to be personally informed of this study. Permanent access to the EGB database was granted for

Abstract

Until 2018, cervical cancer screening in France was an unorganized individual screening, with the exception of some pilot programs in some territories. We aimed to assess, before the implementation of organized cervical cancer screening and human papillomavirus (HPV) nonavalent vaccine introduction in the vaccination schedule in 2018, (i) the individual cervical cancer screening coverage, (ii) the management of squamous intraepithelial lesions (SIL) and (iii) the related costs. We used the *Syst me National des Donn es de Sant * (SNDS) (Echantillon G n raliste de B n ficiaires [EGB] and Programme de M dicalisation des syst mes d'information [PMSI]) to assess the cervical screening coverage rate in France between January 1st, 2012 and December 31st, 2014, and to describe diagnostic investigations and therapeutic management of SIL in 2013. After extrapolation to the general population, a total of 10,847,814 women underwent at least one smear test over the 3-year study period, corresponding to a coverage rate of 52.4% of the women aged 25 to 64 included. In 2013, 126,095 women underwent HPV test, 327,444 women underwent colposcopy, and 9,653 underwent endocervical curettage; 31,863 had conization and 12,162 had laser ablation. Besides, 34,067 women experienced hospital stays related to management of SIL; 25,368 (74.5%) had high-grade lesions (HSIL) and 7,388 (21.7%) low-grade lesions (LSIL). Conization was the most frequent in-hospital therapeutic procedure: 89.5% (22,704) of women with an in-hospital procedure for HSIL and 64.7% (4,781) for LSIL. Mean cost of smear test, colposcopy and HPV tests were around 50 . Total cost for hospital stays in 2013 was estimated at M41 , or a mean cost of 1,211  per woman; 76% were due to stays with HSIL. This study highlights the low coverage rate of individual cervical cancer screening and a high burden related to SIL management.

Inserm units according to French legislation, and permission to extract and use the PMSI data by the consultancy company was obtained from the National Commission on Informatics and Liberty (CNIL; authorization n° 1976885). The SNDS security repository is provided for by the law n° 2016-41 of January 26th, 2016 of modernization of the French health system (Title VI of the Public Health Code) to ensure personal data confidentiality and integrity. The SNDS must not contain any directly identifying data. Any access to an SNDS dataset should only be open for a fixed period, in accordance with the period specified in the authorization granted by the CNIL or other conditions provided for by law, and for trained, qualified and authenticated users. Data can be requested from the National Health Data Institute at: Institut National des Données de Santé (INDS), Postal address: 19 rue Arthur Croquette, 94220 Charenton-le-Pont – FRANCE, Phone number: +33 1 45 18 43 90, Email address: contact@indsante.fr, Website: <https://www.indsante.fr>.

Funding: The study was supported by SPMSD / MSD Vaccins. André Dahlab, Xavier Bresse and Mathieu Uhart are former employees of SPMSD. MSD Vaccins. Xavier Bresse is an employee of MSD vaccins. SPMSD / MSD Vaccins were involved in the study design, data analysis, decision to publish, and preparation of the manuscript. Charlotte Cancalon, Audrey Lajoinie and Stève Bénard are employees of stève consultants. stève consultants did not fund the study but was in charge of designing and performing the study. Yann de Rycke, Florence Tubach, Alexandre Lafourcade, Sylvie Guillo and Marie Dalichamp received no specific funding for this work. Christine Bergeron and Héléne Borne have been rewarded by SPMSD / MSD Vaccins as members of the study Independent Scientific Committee.

Competing interests: The study was supported by SPMSD / MSD Vaccins. André Dahlab, Xavier Bresse and Mathieu Uhart are former employees of SPMSD. Xavier Bresse is an employee of MSD vaccins, which is the current market authorization holder of Gardasil®, Human papillomavirus 9-valent vaccine, recombinant. Charlotte Cancalon, Audrey Lajoinie and Stève Bénard are employees of stève consultants, the commercial company responsible for designing and implementing the study. Christine Bergeron and Héléne Borne received funds from by SPMSD / MSD Vaccins. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials. Yann de Rycke, Florence Tubach, Alexandre Lafourcade,

Introduction

Cervical cancer is the fourth most frequent cancer in women worldwide for both incidence and mortality, with an estimated 570,000 cases and 311,000 deaths in 2018 [1]. In France, the projections from *Santé Publique France* and the French National Cancer Institute in 2017 were 2,840 estimated incident cases, corresponding to an incident rate of 6.0 per 100,000 persons per year, and 1,080 deaths, corresponding to a mortality rate of 1.7 per 100,000 [2].

It is now universally accepted that almost all cervical cancers are due to infection with human papillomavirus (HPV) [3,4]. HPV is the most common viral infection of the reproductive tract; most sexually active women and men will be infected during their life [4]. When an infection with high-risk HPV persists, it may lead to precancerous lesions either low grade squamous intraepithelial lesions (LSIL) for type 1 cervical intraepithelial neoplasia (CIN 1) or high grade squamous intraepithelial lesions (HSIL) for CIN 2 and 3. These precancerous lesions may progress to a cervical cancer within 10 to 20 years of evolution. To date, a total of 13 HPV genotypes have been classified as cervical carcinogens by the International Agency for Research on Cancer (IARC) [5]. HPV genotypes 16 and 18 would be responsible for about 50% of HSIL [6,7] (*i.e.* CIN 2 and 3) and about 70% of cervical cancers [8].

Advances in knowledge on pathological process and characterization of detectable HSIL have made cervical cancer an ideal candidate for prevention program, with an expected positive public health impact [9,10]. HPV vaccination and cervical smear test are the best ways to prevent cervical cancer. The prophylactic vaccination is part of primary prevention and the last vaccine, against 9 types of HPV, was included in the 2018 vaccination schedule in France [11,12]. The vaccination has been recommended for all girls aged 11 to 14 years, and with a possible catch-up for girls aged 15 to 19 years not vaccinated. Screening for cervical cancer is part of secondary prevention. It is based on a cervical smear test called “pap test”. The smear is taken by gynaecologist or midwife and less often by a general practitioner or lab biologist, in a simple and painless way. From the cervical smear, a cytological examination is performed and consists of a morphological analysis of cervical cells to detect early the presence of abnormal and precancerous cells that can develop into cancerous lesions [13] [14]. The HPV test could also be performed. It is a molecular detection method that allows the detection of nucleic acids in high-risk HPV genotypes [14]. Until 2018, cervical cancer screening in France was an unorganized individual screening, with the exception of some pilot programs in some territories [15]. The national organized screening program was one of the major actions of the 2014–2019 cancer plan [16], and since the decree of May 4, 2018, organized cervical cancer screening is part of health programmes (Article L. 1411–6 of the Public Health Code), which already included the organized breast and colorectal cancer screening programmes [17]. The organized cervical cancer screening is recommended for all sexually active women aged 25 to 65 years, every three years, after two negative smears taken one year apart [18]. The smear is covered by French health insurance, and as part of organized screening programmes is free of charge for women with very low incomes [19].

In addition to the cervical smear and HPV tests, other confirmatory diagnostic tools are used as biopsy, colposcopy to identify abnormalities in the mucous membrane of the cervix and to specify its topography, and curettage to research a glandular or squamous endocervical lesion [20]. Therapeutic management can be based on surgery, which consists of removing a fragment of the cervix (conization or partial hysterectomy) or the entire uterus (hysterectomy), or based on treatment by chemotherapy and radiotherapy [21].

We aimed to assess, before the implementation of organized cervical cancer screening and HPV nonavalent vaccine introduction in the vaccination schedule in 2018, (i) individual cervical cancer screening coverage, (ii) the management of SIL and (iii) associated costs, using the French health insurance databases.

Sylvie Guillo, and Marie Dalichampt do not have competing interest in the context of this study.

Materials and methods

Data source

We used claims data from the *Système National des Données de Santé* (SNDS), more specifically the *Echantillon Généraliste de Bénéficiaires* (EGB), a 1/97th random sample of the French health Insurance database that contains data for 670,000 beneficiaries [22]. The EGB is an anonymized reimbursement database built by a random selection of individual identification numbers, representative of the French population by age and by sex. It notably contains anonymised individual data on patient's sociodemographic characteristics, outpatient medical and paramedical care, reimbursed drugs delivered by community pharmacies, laboratory tests, inpatient healthcare, related expenditures, outpatient medical procedures (including SIL diagnosis, investigations and therapeutic management), and, if applicable, patient's date of death.

We also used another database from the SNDS, the national hospital discharge summary database to assess hospital activity (*Programme de médicalisation des systèmes d'information*, PMSI). The PMSI database provided information on hospitalized patients, notably demographic (e.g. sex, age, gender, department and region of residence) and medical data (e.g. dates of start and end of stays, length of stay, reasons for hospital admission, medical unit(s) of stays, medical procedures performed during the stay, costly drugs dispensed during the stay, and, where applicable, hospital inpatient date of death). The PMSI database also contains costs for each hospital stay [23]. Discharge diagnoses are coded using the International Classification of Diseases (ICD-10) [24]. [25–27].

Study design

Cervical cancer screening coverage. A cross-sectional analysis was conducted to identify all smear tests performed in France between January 1st, 2012 and December 31st, 2014 among all-age women including children. This study period was defined considering the 3 year-interval recommended between two smear test [28], allowing the estimation of population coverage. It included the most recent data at the date of the analyses.

Annual management of squamous intraepithelial lesions (SIL): diagnosis, therapeutic procedures and hospital stays related to SIL. A cross-sectional analysis was performed to describe SIL diagnosis investigations, therapeutic management and hospital stays related to SIL from January 1st, 2013 to December 31st, 2013 among all-age women including children.

Data collection

Procedures of interest were identified: smear tests, diagnosis investigations, therapeutic management (performed in the community, outpatient visit or in-hospital management). For each procedure, patient's age and cost of the procedure were extracted. For each hospital stays of interest (i.e. related to SIL management), we collected patient's age, severity of SIL (low, high or undetermined-grade), type of ward for the stay (medical or surgical), type of hospitalisation (day or conventional hospitalisation), and cost of the stay.

Cervical cancer screening coverage. Smear tests performed during outpatient visits (either in the community or at hospital/clinic setting) between January 1st, 2012 and December 31st, 2014 were identified in the EGB database using standard codes of medical procedures (CCAM coding system), healthcare professional codes (NAGP coding system) and laboratory tests (NABM coding system).

Selected procedures included both cervical cell sampling and acts related to cytology exams. Codes for cervical cell sampling included acts performed by gynaecologists or generalist practitioners (GP; CCAM code JKHD001 in the community; CCAM code JKHD001 and NGAP

code K-3 for outpatient visits), by midwives (NGAP codes SF-3,6 for 2012–2013 and SF-4,1 for 2014), or by laboratories (NABM code 9053). Procedures related to cytology exams are processed by laboratories (NABM code 0013; CCAM codes JKQP001 and JKQP008 before March 2014, and JKQX001, JKQX008, JKQX015 and JKQX027 after March 2014).

Smear tests were accounted on year N (i) if a cervical cell sampling and a cytology exam were performed in a timeframe shorter than 30 days, or (ii) in the absence of any cell sampling on year N, if a cytology exam was performed between February 1st, and December 31st for the year studied (January has not been considered in order not to take into account cell samplings performed in December year N-1), or (iii) in the absence of any cytology exam on year N, if a cervical cell sampling was performed during the month of December of year N (to take into account cell sampling whose cytology exam can be performed over the following year).

Annual management of squamous intraepithelial lesions (SIL): Diagnosis and therapeutic procedures and hospital stays related to SIL. Diagnosis investigations, therapeutic management and hospital stays related to SIL and occurring in 2013 were identified using CCAM and NABM codes for procedures, and ICD-10 codes for hospital discharge diagnosis.

Diagnosis investigations included (i) tests for carcinogenic HPV processed by laboratories (NABM codes 0024 and 4127; CCAM code ZZQP173); and procedures performed by gynaecologists or GP, (ii) colposcopies (CCAM code JLQE002), (iii) biopsies (CCAM code JKHA002) and (iv) cervical curettage (CCAM code JKGD003).

Therapeutic management comprised all SIL specific cervical surgical procedures exclusively performed by gynaecologists or GP. We extracted (i) laser-free destruction of SIL lesions, including cryotherapy and cold coagulation (CCAM code JKND004), (ii) laser ablation (CCAM codes JKND003 and JKND002), (iii) cold knife or laser conization (CCAM code JFKA031), (iv) large loop excision of the transformation zone (LLETZ; CCAM codes JKFD002 and JKFE003), and (v) surgery, including trachelectomy and colpotrachelectomy (CCAM codes JKFA008, JKFA009, JKFA011, JKFA019 and JKFA030).

Women hospitalized for SIL or carcinoma *in situ* as principal, secondary or associated diagnosis were identified through the selection of any hospital stay with ICD-10 diagnosis code N87* (Dysplasia of cervix uteri (low, high or undetermined-grade)) or D06* (Carcinoma *in situ* of cervix uteri; [Table 1](#)). Stays with ICD-10 code for cervical cancer (C53) were excluded from the analysis, as the study focused on SIL lesions. Stays with diagnosis codes of interest were excluded if they were recorded for a male patient. Lastly, stays without any procedure code related to the diagnosis or treatment of SIL were reviewed using all diagnoses and procedures coded during the stay in order to select only those compatible with SIL management.

Statistical analysis

Since the EGB database is a random sample of the French National Health Insurance, results presented in this article have been extrapolated to the overall French female population. The extrapolation coefficients from EGB to the general population of women corresponded to the ratio of the number of women in the EGB in 2012 reported to the female French population as of January 1st, 2013 by 5-year age class, and are presented in [S1 Table](#). The number of women in the general population was obtained from the *Institut national de la statistique et des études économiques* [INSEE].

Quantitative data are expressed as means and standard deviations or medians and inter-quartile range (IQR) for non-normally distributed variables. Categorical data are described using numbers and percentages.

Table 1. List of ICD-10 codes selected for the identification of hospital stays with CIN or carcinoma *in situ* as principal, secondary or associated diagnosis.

Pathology	ICD-10 code	Description
Dysplasia of cervix uteri	N87	Dysplasia of cervix uteri
	N870	Mild cervical dysplasia Cervical intraepithelial neoplasia [CIN], grade I
	N871	Moderate cervical dysplasia Cervical intraepithelial neoplasia [CIN], grade II
	N872	Severe cervical dysplasia, not elsewhere classified Severe cervical dysplasia NOS Excl.: cervical intraepithelial neoplasia [CIN], grade III, with or without mention of severe dysplasia
	N879	Dysplasia of cervix uteri, unspecified
Carcinoma in situ of cervix uteri	D06	Carcinoma in situ of cervix uteri Incl.: cervical intraepithelial neoplasia [CIN], grade III, with or without mention of severe dysplasia Excl.: melanoma in situ of cervix (D03.5), severe dysplasia of cervix NOS (N87.2)
	D060	Carcinoma in situ of endocervix
	D061	Carcinoma in situ of exocervix
	D067	Carcinoma in situ of other parts of cervix
	D069	Carcinoma in situ of cervix, unspecified

NOS, not otherwise specified

<https://doi.org/10.1371/journal.pone.0228660.t001>

Total number of smear tests and number of women with at least one smear test were calculated for the whole population of all age women. The cervical cancer screening coverage rate was then calculated (i) for all-age women, and (ii) for women aged between 25 and 64 included in order to estimate the adherence to French guidelines for cervical cancer screening that recommend screening in this age stratum [28]. The rate was estimated per age group by calculating the proportion of women that underwent at least one smear test between January 1st, 2012 and December 31st, 2014 reported to the size of the French female population, on January 1st, 2013 [29].

Cervical cancer screening coverage was reported by patient’s age categories considering 5-year age groups, and components of disease management (diagnosis investigations, therapeutic management and hospital stays) were reported for all women. Hospital stays were presented by severity level of the CIN lesion. Stays recorded with different severity grades were classified according to the most severe.

An economic analysis has been performed determining costs related to smear test, diagnosis investigation, therapeutic management and hospital stays related to SIL, by item of expenditures, from a collective perspective including direct medical costs. Mean cost per patient for procedures performed during outpatient visits presented for reimbursement has been extracted. Inpatient healthcare costs were estimated per hospital stay, based on the French national Diagnosis Related Group (DRG). The DRG is determined, for a given stay, based on recorded discharge diagnosis and classifying procedures performed during the stay. Costs related to each DRG—*i.e.* that cover treatments (except expensive drugs), medical procedures, nursing and physician fees—is assessed on the basis of the annual national cost study (ENCC). Costs are reported in Euros (€), year 2016, with costs prior to 2016 being revalued according to a consumer price index—health data index (4011-E)—published by INSEE [30].

All analyses were performed using SAS[®] V9.3 (SAS Institute Inc. Cary, NC, USA).

Ethics

Study methods were validated by a multidisciplinary qualified independent scientific committee (ISC). This observational study used solely existing claims data (SNDS, including EGB and PMSI databases). According to the French legislation at the time of study implementation, process to access such administrative database did not involve submission to an ethics committee. Since the study used existing data from the SNDS, patients did not need to be personally informed of this study. Permanent access to the EGB database was granted for Inserm units according to French legislation, and permission to extract and use the PMSI data by the consultancy company was obtained from the National Commission on Informatics and Liberty (CNIL; authorization n° 1976885). The SNDS security repository is provided for by the law n°2016–41 of January 26th, 2016 of modernization of the French health system (Title VI of the Public Health Code) to ensure personal data confidentiality and integrity. The SNDS must not contain any directly identifying data. Any access to an SNDS dataset should only be open for a fixed period, in accordance with the period specified in the authorization granted by the CNIL or other conditions provided for by law, and for trained, qualified and authenticated users.

Results

Cervical cancer screening coverage (2012–2014)

Between January 1st, 2012 and December 31st, 2014, a total of 15,145,887 smear tests were performed in all-age women. The total number of smear tests performed per year was 5,099,325 in 2012, 5,097,960 in 2013, and 4,948,602 in 2014. This corresponds to a total number of 10,847,814 women with at least one smear test performed for the whole female population over the recommended 3-year interval, corresponding to 4,906,170–4,901,131 and 4,758,381 women in 2012, 2013 and 2014, respectively. Among women with at least one smear test over the study period, the mean number of smear tests per woman per year remained stable for the 3 years studied, at 1.40.

The overall screening coverage rate in 25–64 years inclusive age group women over the 3-year study period was 52% of the women. It was 56 to 58% among the 30–49 age categories and decreased in older age groups to reach 40% among 60–64 years inclusive and 34% among 65–69 age group women (Fig 1).

Annual management of squamous intraepithelial lesions (SIL): Diagnosis and therapeutic procedures and hospital stays related to SIL in 2013

Concerning diagnosis investigations, 131,172 HPV tests were performed in 2013, corresponding to 126,095 women with at least one HPV test over the study period of, accounting for 2.6% of women with at least one smear test over the year (Table 2). Over the same year, 327,444 women underwent at least one colposcopy with a total of 369,967 colposcopies. Only 45,779 biopsies have been identified in 2013, processed in 43,173 women. Lastly, curettage accounted for 9,653 procedures in 9,653 women.

Regarding SIL therapeutic management, for recommended procedures, 36,661 conizations and 15,162 laser ablations were performed in 2013; this corresponds to a number of 31,863 and 12,162 women who underwent at least one of those procedures, respectively (Table 2). Lastly, 13,737 laser-free destruction procedures and 12,456 LLETZ were performed in 2013.

In 2013, 34,067 women were hospitalized with a diagnosis of SIL (corresponding to 1.03 % French women in 2013), for a total number of 35,555 hospital stays related to management of




Fig 1. Cervical cancer screening coverage rate in France over 2012–2014 (between January 1st, 2012 and December 31st, 2014), i.e. proportion of women with at least one smear test performed within the 3-year period reported to the size of the French female.

<https://doi.org/10.1371/journal.pone.0228660.g001>

SIL (Table 2). Among those women, 25,368 (74.5%) had HSIL (CIN 2+), with a mean age of 38.6 ± 11.0 years old; they experienced a total of 26,760 stays, or a mean number per woman of 1.05 stays over the year (Table 3). Women with LSIL (CIN 1) accounted for 7,388 (21.7%),

Table 2. SIL management in 2013, all-age women in the general population*.

	Number of events	Number of women with at least one event
Diagnosis investigation		
Smear tests	5,097,960	4,901,131
HPV test	131,172	126,095
Colposcopy	369,967	327,444
Biopsy	45,779	43,173
Curettage	9,653	9,653
Therapeutic management		
Conization**	36,661	31,863
Laser ablation	15,162	12,162
Laser-free destruction***	13,737	12,561
LLETZ	12,456	11,221
Hospital stays		
Hospital stays with diagnosis of SIL or carcinoma in situ	35,555	34,067

* Results presented for the general population of women from the coefficients of extrapolation of EGB described in S1 Table.

** Laser or cold knife

*** Including cryotherapy and cold coagulation

<https://doi.org/10.1371/journal.pone.0228660.t002>

Table 3. Hospital stays related to management of SIL, all-age women in the general population*.

	HSIL	LSIL	Lesions of unknown grade	Total
Number of women	25,368	7,388	1,311	34,067
Number of hospital stays	26,760	7,455	1,340	35,555
	n (% of stays)	n (% of stays)	n (% of stays)	
Nature of the stay				
Surgery	26,131 (97.6)	7,261 (97.4)	1,132 (84.5)	34,524 (97.1)
Medicine	629 (2.4)	194 (2.6)	208 (15.5)	1,031 (2.9)
Type of hospitalisation				
Day hospitalisation	21,575 (80.6)	6,336 (85.0)	931 (69.5)	28,842 (81.1)
Conventional hospitalisation	5,185 (19.4)	1,119 (15.0)	409 (30.5)	6,713 (18.9)
	n (% of women)	n (% of women)	n (% of women)	
In-hospital procedures**				
Conization***	22,704 (89.5)	4,781 (64.7)	744 (56.8)	28,229 (82.9)
Curettage	2,480 (9.8)	561 (7.6)	67 (5.1)	3,108 (9.1)
Laser ablation	1,169 (4.6)	1,709 (23.1)	95 (7.2)	2,973 (8.7)
Surgery****	1,916 (7.6)	392 (5.3)	11 (0.8)	2,319 (6.8)
Laser-free destruction*****	108 (0.4)	184 (2.5)	11 (0.8)	303 (0.9)

*Results presented for the general population of women from the coefficients of extrapolation of EGB described in S1 Table.

** Only in-hospital procedures are accounted; both outpatients and inpatient procedures are accounted to assess the burden of the disease in Table 2. A same woman could have had more than one procedure.

*** Laser or cold knife

**** Trachelectomy and colpotrachelectomy.

***** Including cryotherapy and cold coagulation

<https://doi.org/10.1371/journal.pone.0228660.t003>

with a mean age of 40.3 ± 12.1 years old; they experienced a total of 7,455 stays, or 1.01 hospitalisation per woman. Lastly, 1,311 (3.8%) women had unspecified grade, with a mean age of 43.9 ± 12.7 years old; the total number of stays was 1,340, or a mean number of 1.02 stay per woman.

Surgical hospital stays represented the large majority of stays related to SIL management, regardless of the SIL grade (97.6% of all stays for high grade, 97.4% for low grade and 84.5% for undetermined; Table 3). Most of stays corresponded to day admissions (80.6% of all stays for HSIL, 85.0% for LSIL and 69.5% for undetermined; Table 3).

Regarding in-hospital management, most of women underwent a cervical conization during the stay, which was the most used therapeutic management for all SIL grade: 89.5% for women with HSIL, 64.7% for LSIL and 56.8% for undetermined (Table 3). Other major procedures for hospitalized SIL were diagnostic curettage, surgery, and laser ablations (Table 3).

Economic analysis

Mean cost per procedure for diagnosis and therapeutic procedures was based on outpatient and inpatient costs. The mean cost for a complete smear test (*i.e.* a cervical smear test associated with a cytological examination) was 56.5 ± 26.9 €, and the mean cost for HPV test was 41.1 ± 7.9 €. Concerning management related to SIL in hospital, the average cost per hospital stay for women with HSIL was $1,177.3 \pm 1,046.9$ €, corresponding to a total cost of 31,504,548 € for the total number of 26,760 stays (Fig 2). The mean cost per hospital stay for women with LSIL was $1,032.1 \pm 812.0$ €, or a total cost for the 7,455 stays of 7,694,305 €. Lastly, the average cost per hospital stay where SIL grade was undetermined was $1,544.0 \pm 1,397.8$ €, with a total




Fig 2. Distribution of costs arising from hospital stays related to CIN management in 2013, depending on CIN grade.

<https://doi.org/10.1371/journal.pone.0228660.g002>

cost of 2,068,960 € for the 1,340 stays. The total cost for hospital stays in 2013 was estimated at 41,267,068 € for the 34,067 women who were hospitalized with a diagnosis of SIL, or a mean cost of 1,211 € per woman. Seventy-six per cent of the total cost arisen from stays with HSIL diagnosis; stays with LSIL accounted for 19% of total costs.

Discussion

This study, based on the French SNDS (EGB and PMSI databases), provides robust data on cervical cancer screening and on the burden of SIL lesions before the implementation of the organized cervical cancer screening and the introduction of the HPV non avalent vaccine. Indeed, health care consumption data recorded into this database presents the main advantage to be prospectively and exhaustively collected, independently of the study. The present study focused on outpatient and in-hospital diagnosis investigations and therapeutic management of SIL lesions; the management of potentially HPV-related cancers has already been assessed within a first observational study based on the French SNDS [31].

The screening coverage rate was estimated to be 52% in the French female population aged 25 to 65 years. The result is consistent with coverage rates measured in older French studies, ranging between 53% (2009–2011) and 62% (2010–2012) [32–37]. Although the targeted female population is mostly covered in France, coverage rate remains insufficient in regards of the objective in terms of cervical cancer screening coverage rate of 80% recommended by the French Cancer Plan 2014–2019 [38]. Cervical cancer screening coverage rate in France also seems to be below those of northern European countries [39]. On the other hand, women with at least one smear test within the 3-year of the study period had a mean number of 1.40 smear test per woman, suggesting an over screening. Similar results have been found in the French study conducted on the French health insurance databases, where the mean number of smear

tests per women with at least one smear test was estimated at 1.5 in 25–64 years old women [40]. The 60–64 age group had the lowest coverage rate (40.3%) of the population targeted by the screening; this suggests the need of a strengthened screening policy for this age group, otherwise the lack of surveillance associated with population ageing could lead to an increase in number of cervical cancer in the future.

However, these findings have to be interpreted in light of study limitations. Notably, smear tests performed during hospital stays cannot be identified in the EGB database; while the proportion of smear tests performed during hospital stays has been estimated at 6.5% [41]. Thus, it is reasonable to believe that the screening rate observed in our study is slightly underestimated. Besides, the coding system does not allow us to distinguish screening smear tests from follow-up smear tests. Lastly, another argument supporting an underestimation of the number of smear tests is that cytology exam performed in January were not accounted as a smear test if no cervical cell sampling were recorded over the study period.

In France, HPV tests are only reimbursed in case of smear tests evocating ASC-US (Atypical Squamous Cells of Undetermined Significance) [42]. From the literature, ASC-US represented 2.5% of all HPV tests performed in 2008 in France; this is in accordance with our results showing that 131,172 HPV tests were performed in 2013, representing 2.6% of all smear tests [43]. The number of biopsies found using the CCAM code JKHA002 cannot be interpreted because the CCAM code for colposcopy (JLQE002) also includes an eventual biopsy. In addition, the codes for cervical biopsies (NGAP 004), for cervical curettage (NGAP 007) and conizations (NGAP 008) read in biological laboratories are non-specific and were therefore not used in this study, potentially leading to an underestimation. Conization—inclusion cold knife and laser conization—was performed in 31,863 women in 2013. The number of women having undergone destruction ($n = 12,162$) could have been slightly overestimated since the coding system for laser ablation also encompasses other lesions such as vulvar, vaginal, and perianal lesions. However, these lesions are very sparse and can be considered as negligible compared with SIL [7,40,41]. Moreover, the number of laser-free destruction procedures and LLETZ (13,737 and 12,456, respectively) was not negligible. These procedures were not recommended for the management of SIL at the study period; but currently the use of LLETZ for carcinoma *in situ* and HSIL with a satisfactory colposcopy is recommended since the 2016 guidelines [42].

The analysis of hospital data allowed us to describe the in-hospital management of SIL. The total number of women hospitalized for a high grade ($n = 25,368$) or a low grade lesion ($n = 7,388$) is in accordance with previous data [7,43], accounting for respectively 8 and 2 women per 10,000 for the whole women population in France in 2013. This trend contrasts with those observed on other countries, such as Denmark, where high coverage rates for both cervical cancer screening and HPV vaccination, through a national HPV vaccination program, has been found to significantly decrease the number of SIL [7,44]. Among women hospitalised with diagnosis of HSIL, the proportion of patients that underwent conization (89.5%), surgery (9.8%) or laser ablation (4.6%) is in line with recommendations of French Health authorities [45]. HSIL should indeed always be treated and conization is the treatment of choice. To the opposite, treatment of low grade lesions is not systematic and hospital admission as well as conization are not systematically recommended. Mainly, from most recent recommendations from the French National Cancer Institute (*Institut National du Cancer*, INCa), treatment of LSIL lesions should only be considered for lesions that persisted after a 2-year monitoring period, with visit frequency depending on cytology results or HPV test results [42]. Our results indicate that 7,388 women were hospitalized with diagnosis a LSIL lesion in 2013, and 65% of them underwent conization. Similar findings have already been observed in a French study conducted on year 2004, where 6,637 hospital admission with LSIL diagnosis have been

identified, and 3,693 conizations were performed [46]. Since conization may result in severe complications, especially in women of childbearing age, such as miscarriages in the second semester [47,48] or premature births [49,50], the risk/benefit balance of this procedure should be carefully assessed in each woman. Also, the organized cervical cancer screening program provides a homogenization of the management of abnormal smear tests to avoid excessive conizations and to reduce over-treatment [38]. Moreover, the HPV vaccine is a primary prevention measure that would prevent SIL, and the overtreatment and additional costs related with the treatment of these lesions. Surgical hospital stays represented the vast majority of stays related to SIL management while most of stays corresponded to day admissions. This result can be explained by a high ratio of conization performed as outpatient visit; thus most patients leave the hospital on the same day.

Mean costs of the diagnosis and treatment procedures were estimated based on costs presented to the reimbursement, as registered into the French Health Insurance databases. The total cost for hospital stays in 2013 was estimated at M41 €, or a mean cost of 1,211 € per woman; 76% were due to stays with HSIL diagnosis, and 19% to stays with LSIL.

Events of interest were identified through the SNDS, widely used and well-known tool for pharmaco-epidemiological and health economics studies [25]. Being aware of potential limits related to the use of these databases—mainly limited clinical details, limited validity of ICD coding -, we took special care to develop an optimized algorithm that properly identified all procedures related to SIL diagnosis and management. However, these results have to be interpreted in light of the limits of the study. Some procedures such as biopsy or LLETZ may indeed be under- or miscoded because of low financial valuation. However our results were shown to be consistent with figures reported by the French Health authorities and French epidemiological studies [28,41,43,49].

Conclusion

This study highlights the low coverage rate of individual cervical cancer screening and the high burden of SIL, in terms of diagnostic investigations, therapeutic management and costs, in the French women population. These results must now be compared with those after implementation of the organized cervical cancer screening.

Supporting information

S1 Table. Coefficient of extrapolation of EGB to the general population in women.
(DOCX)

Acknowledgments

The authors thank Coralie LECOMTE and Anaïs HAVET of **stève** consultants for revising this manuscript.

Author Contributions

Conceptualization: Florence Tubach, Marie Dalichampt, Stève Bénard.

Formal analysis: Yann de Rycke, Alexandre Lafourcade, Charlotte Cancalon.

Investigation: Yann de Rycke, Alexandre Lafourcade, Charlotte Cancalon.

Methodology: Florence Tubach, Marie Dalichampt, Christine Bergeron, Hélène Borne, Charlotte Cancalon, Stève Bénard.

Supervision: Sylvie Guillo.

Validation: Christine Bergeron, H el ene Borne, St eve B enard.

Writing – original draft: Audrey Lajoinie.

Writing – review & editing: Andr e Dahlab, Xavier Bresse, Mathieu Uhart, Christine Bergeron, H el ene Borne, Charlotte Cancalon, St eve B enard.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018; 68: 394–424. <https://doi.org/10.3322/caac.21492> PMID: 30207593
2. INCA. Projection de l'incidence et de la mortalit e par cancer en France m etropolitaine en 2017. Available: https://www.e-cancer.fr/content/download/220859/3008146/file/Projection_de_l_incidence_et_de_la_mortalite_en_France_metropolitaine_en_2017_mel_20180108.pdf
3. Pr etet J-L, Jacquard A-C, Carcopino X, Charlot J-F, Bouhour D, Kantelip B, et al. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. *Int J Cancer*. 2008; 122: 428–432. <https://doi.org/10.1002/ijc.23092> PMID: 17893882
4. WHO | Human papillomavirus (HPV) and cervical cancer. In: WHO [Internet]. 2018 [cited 4 Feb 2019]. Available: [https://www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus-\(hpv\)-and-cervical-cancer](https://www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer)
5. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE. Carcinogenicity of human papillomaviruses. *Lancet Oncol*. 2005; 6: 204. [https://doi.org/10.1016/s1470-2045\(05\)70086-3](https://doi.org/10.1016/s1470-2045(05)70086-3) PMID: 15830458
6. Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States—2008–2012. *Vaccine*. 2015; 33: 1608–1613. <https://doi.org/10.1016/j.vaccine.2015.01.084> PMID: 25681664
7. Hartwig S, Baldauf J-J, Dominiak-Felden G, Simondon F, Alemany L, de Sanjos e S, et al. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. *Papillomavirus Res*. 2015; 1: 90–100. <https://doi.org/10.1016/j.pvr.2015.06.003>
8. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int J Cancer*. 2017; 141: 664–670. <https://doi.org/10.1002/ijc.30716> PMID: 28369882
9. Dupont N. Coloscopie et Pathologies du Col. Point sur l' epid emiologie et le d epistage du cancer du col de l'ut erus en France. MISES   A JOUR EN GYN ECOLOGIE OBST ETRIQUE TOME XXXIII. Coll ege National des Gyn ecologues et Obst etriciens Fran ais; 2009. p. 455.
10. Haute Autorit e de Sant e - D epistage et pr evention du cancer du col de l'ut erus. Actualisation du r ef erentiel de pratiques de l'examen p eriodique de sant e (EPS) Juin 2013. 24 Nov 2016 [cited 24 Nov 2016]. Available: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-08/referentieleps_format2clic_kc_col_uterus_2013-30-08_vf_mel.pdf
11. Zhai L, Tumban E. Gardasil-9: A global survey of projected efficacy. *Antiviral Res*. 2016; 130: 101–109. <https://doi.org/10.1016/j.antiviral.2016.03.016> PMID: 27040313
12. Calendrier des vaccinations et recommandations vaccinales 2018. Minist ere des solidarit es et de la sant e. Available: https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinations_2018.pdf
13. Conchez V, Cocq CL. D epistage du cancer du col de l'ut erus: zoom sur une d emarche novatrice en Gironde. 2012; 11.
14. HAS. Juillet 2019.  valuation de la recherche des papillomavirus humains (HPV) en d epistage primaire des l esions pr ecanc ereuses et canc ereuses du col de l'ut erus et de la place du double immuno-marquage p16/Ki67.
15. Hamers FF. COUVERTURE DU D EPISTAGE DU CANCER DU COL DE L'UT ERUS EN FRANCE, 2012–2017. *BEH* 22–23. 2019; 417–423.
16. Sant e Publique France. Evaluation du programme de d epistage du cancer du col de l'ut erus. 16 Jul 2019 [cited 12 Dec 2019]. Available: /maladies-et-traumatismes/cancers/cancer-du-col-de-l-uterus/evaluation-du-programme-de-depistage-du-cancer-du-col-de-l-uterus
17. Arr et e du 4 mai 2018 relatif   l'organisation du d epistage organis e du cancer du col de l'ut erus.

18. LE CANCER DU COL DE L'UTERUS: ETAT DES CONNAISSANCES EN 2014. Available: http://beh.santepubliquefrance.fr/beh/2014/13-14-15/pdf/2014_13-14-15_1.pdf
19. Mignot S, Ringa V, Vigoureux S, Zins M, Panjo H, Saulnier P-J, et al. Pap tests for cervical cancer screening test and contraception: analysis of data from the CONSTANCES cohort study. *BMC Cancer*. 2019; 19: 317. <https://doi.org/10.1186/s12885-019-5477-8> PMID: 30952209
20. ANAES. Conduite à tenir devant une patiente ayant un frottis cervico-utérin anormal. Septembre 2002. Available: https://www.has-sante.fr/upload/docs/application/pdf/frottis_final_-_recommandations.pdf
21. Haute Autorité de Santé. La prise en charge d'un cancer du col de l'utérus. Juin 2010. Available: https://www.has-sante.fr/upload/docs/application/pdf/2010-09/ald30_gp_coluterin_web.pdf
22. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. *Rev D'Épidémiologie Santé Publique*. 2010; 58: 286–290.
23. Rémy V, Mathevet P, Vainchtock A. Vulvar and vaginal cancers and dysplasia in France—an analysis of the hospital medical information system (PMSI) database. *Eur J Obstet Gynecol Reprod Biol*. 2009; 147: 210–214. <https://doi.org/10.1016/j.ejogrb.2009.08.011> PMID: 19735968
24. World Health Organization International Classification of Diseases. ICD-10 Version: 2016. [cited 15 Nov 2017]. Available: <http://apps.who.int/classifications/icd10/browse/2016/en>
25. Moulis G, Lapeyre-Mestre M, Palmaro A, Pugno G, Montastruc J-L, Sailler L. French health insurance databases: What interest for medical research? *Rev Médecine Interne*. 2015; 36: 411–417. <https://doi.org/10.1016/j.revmed.2014.11.009> PMID: 25547954
26. Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. *Pharmacoepidemiol Drug Saf*. 2017; 26: 954–962. <https://doi.org/10.1002/pds.4233> PMID: 28544284
27. Centers for Medicare and Medicaid Services (CMS), National Center for Health, Statistics (NCHS). ICD-10-CM Official Guidelines for Coding and Reporting. 2017. Available: https://www.cdc.gov/nchs/data/icd/10cmguidelines_2017_final.pdf
28. Haute Autorité de Santé - Dépistage et prévention du cancer du col de l'utérus. Actualisation du référentiel de pratiques de l'examen périodique de santé (EPS) Juin 2013. [cited 24 Nov 2016]. Available: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-08/referentieleps_format2clic_kc_col_uterus_2013-30-08_vf_mel.pdf
29. INSEE—Pyramide des âges au 1er janvier 2013, France. [cited 24 Nov 2016]. Available: <https://www.insee.fr/fr/statistiques/fichier/1913143/pyramide-des-ages-2013.xls>
30. Statistiques | Insee. [cited 22 Nov 2017]. Available: <https://www.insee.fr/fr/statistiques>
31. Abramowitz L, Lacau Saint Guily J, Moyal-Barracco M, Bergeron C, Borne H, Dahlab A, et al. Epidemiological and economic burden of potentially HPV-related cancers in France. *PloS One*. 2018; 13: e0202564. <https://doi.org/10.1371/journal.pone.0202564> PMID: 30235216
32. Institut National du Cancer. Le programme de dépistage organisé du cancer du col de l'utérus. Available: <https://www.e-cancer.fr/Professionnels-de-sante/Depistage-et-detection-precoce/Depistage-du-cancer-du-col-de-l-uterus/Le-programme-de-depistage-organise>
33. Evaluation du programme de dépistage du cancer du col de l'utérus / Evaluation des programmes de dépistage des cancers / Cancers / Maladies chroniques et traumatismes / Dossiers thématiques / Accueil. [cited 3 Jan 2018]. Available: <http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-chroniques-et-traumatismes/Cancers/Evaluation-des-programmes-de-depistage-des-cancers/Evaluation-du-programme-de-depistage-du-cancer-du-col-de-l-uterus>
34. Vers un dépistage organisé - Dépistage du cancer du col de l'utérus | Institut National Du Cancer. [cited 3 Jan 2018]. Available: <http://www.e-cancer.fr/Professionnels-de-sante/Depistage-et-detection-precoce/Depistage-du-cancer-du-col-de-l-uterus/Vers-un-depistage-organise>
35. Beltzer N, Hamers F, Duport N. Résultats finaux de l'évaluation du dépistage du cancer du col de l'utérus organisé dans 13 départements en France, 2010–2014. *Bull Epidémiol Hebd*. 2017; 26–31.
36. Maura G, Chaignot C, Weill A, Alla F, Heard I. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study. *Eur J Cancer Prev*. 2017; Publish Ahead of Print. <https://doi.org/10.1097/CEJ.0000000000000360> PMID: 28368950
37. Direction de la recherche, des études, de l'évaluation et des statistiques, DREES. L'état de santé de la population en France. Rapport 2015. Available: http://drees.solidarites-sante.gouv.fr/IMG/pdf/rappeds_v11_16032015.pdf
38. Plan cancer 2014–2019: priorités et objectifs—Plan cancer | Institut National Du Cancer. [cited 1 Dec 2017]. Available: <http://www.e-cancer.fr/Plan-cancer/Plan-cancer-2014-2019-priorites-et-objectifs>

39. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. *Lancet Glob Health*. 2016; 4: e453–e463. [https://doi.org/10.1016/S2214-109X\(16\)30099-7](https://doi.org/10.1016/S2214-109X(16)30099-7) PMID: 27340003
40. Beltzer N, Hamers F, Duport N. Résultats finaux de l'évaluation du dépistage du cancer du col de l'utérus organisé dans 13 départements en France, 2010–2014. *Bull Epidemiol Hebd*. 2017; 26–31.
41. Bergeron C, Cartier I, Guldner L, Lassalle M, Savignoni A, Asselain B. Lésions précancéreuses et cancers du col de l'utérus diagnostiqués par le frottis cervical. Ile-de-France, enquête Crisap, 2002. *Bull Epidemiologique Hebd*. 2005; 2: 5–6.
42. Institut National du Cancer INCa. Conduite à tenir devant une femme ayant une cytologie cervico-utérine anormale. 2016 Dec. Available: <http://ansfl.org/document/inca-2017-cat-devant-une-femme-ayant-une-cytologie-cervico-uterine-anormale/>
43. Bergeron C, Cohet C, Bouée S, Lorans C, Rémy V. Management of abnormal smears intraepithelial neoplasia and associated treatment costs in France. *BEH n°1*. 2007: 4–6.
44. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia—nationwide follow-up of young Danish women. *J Natl Cancer Inst*. 2014; 106: djt460. <https://doi.org/10.1093/jnci/djt460> PMID: 24552678
45. Haute Autorité de Santé. Management of a patient with an abnormal cervical smear- 2002 update. [cited 30 Nov 2016]. Available: http://www.has-sante.fr/portail/upload/docs/application/pdf/Frottis_anglais.pdf
46. Collège National des Gynécologues et Obstétriciens Français. Recommandations pour la pratique clinique—Prévention du cancer du col de l'utérus. Available: http://www.cngof.fr/pratiques-cliniques/recommandations-pour-la-pratique-clinique/aperçu?path=RPC%2BCOLLEGE%252F2007%252Frpc_prev-K-col2007.pdf&i=21959
47. Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. *BMJ*. 2014; 349: g6192. <https://doi.org/10.1136/bmj.g6192> PMID: 25352501
48. Baldauf J-J, Baulon E, Thoma V, Woronoff A-S, Akladios CY. [Obstetric outcomes following LOOP-excision]. *J Gynecol Obstet Biol Reprod (Paris)*. 2013; 42: 534–540. <https://doi.org/10.1016/j.jgyn.2013.05.004> PMID: 23809573
49. Boubli L, Shojai R, Carcopino X. COLLÈGE NATIONAL DES GYNÉCOLOGUES ET OBSTÉTRICIENS FRANÇAIS. Les conséquences des traitements de la pathologie cervicale. Stérilité, complications obstétricales. 2007 [cited 30 Nov 2016]. Available: http://www.cngof.asso.fr/d_livres/2007_GM_235_boubli.pdf
50. Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaïdi M, Mitra A, Martin-Hirsch PP, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. *Cochrane Database Syst Rev*. 2017; 11: CD012847. <https://doi.org/10.1002/14651858.CD012847> PMID: 29095502